JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5.
about
Role of CHD5 in human cancers: 10 years laterKDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cellsSubstituted 2-(2-aminopyrimidin-4-yl)pyridine-4-carboxylates as potent inhibitors of JumonjiC domain-containing histone demethylasesDifferential expression and sex chromosome association of CHD3/4 and CHD5 during spermatogenesisJMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHIJMJD2A promotes the Warburg effect and nasopharyngeal carcinoma progression by transactivating LDHA expressionKDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumorsArchitects of the genome: CHD dysfunction in cancer, developmental disorders and neurological syndromesOverexpression of KDM4 lysine demethylases disrupts the integrity of the DNA mismatch repair pathway.Biochemical mechanism of DSB end resection and its regulation.Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.RET mutation p.S891A in a Chinese family with familial medullary thyroid carcinoma and associated cutaneous amyloidosis binding OSMR variant p.G513D.Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma.SCF(Fbxo22)-KDM4A targets methylated p53 for degradation and regulates senescence.Global histone modification profiling reveals the epigenomic dynamics during malignant transformation in a four-stage breast cancer model.Nitric oxide modifies global histone methylation by inhibiting Jumonji C domain-containing demethylases.ETS transcription factor ERG cooperates with histone demethylase KDM4A.KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and GlycolysisSilencing of CHD5 gene by promoter methylation in leukemia.The histone demethylase JMJD2A/KDM4A links ribosomal RNA transcription to nutrients and growth factors availability.Jumonji domain-containing protein 2B silencing induces DNA damage response via STAT3 pathway in colorectal cancer.SUMO modification of a heterochromatin histone demethylase JMJD2A enables viral gene transactivation and viral replication.The Chromodomain Helicase DNA-Binding Chromatin Remodelers: Family Traits that Protect from and Promote Cancer.Roles of histone methyl-modifying enzymes in development and progression of cancer.Histone lysine demethylase (KDM) subfamily 4: structures, functions and therapeutic potential.KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Drosophila melanogaster Hsp22: a mitochondrial small heat shock protein influencing the aging process.Epigenomic analysis in a cell-based model reveals the roles of H3K9me3 in breast cancer transformation.The emerging role of lysine demethylases in DNA damage response: dissecting the recruitment mode of KDM4D/JMJD2D to DNA damage sitesHistone demethylase JMJD2B and JMJD2C induce fibroblast growth factor 2: mediated tumorigenesis of osteosarcoma.JMJD2A-dependent silencing of Sp1 in advanced breast cancer promotes metastasis by downregulation of DIRAS3.KDM4C (GASC1) lysine demethylase is associated with mitotic chromatin and regulates chromosome segregation during mitosis.Kdm4b histone demethylase is a DNA damage response protein and confers a survival advantage following γ-irradiation.The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathwayThe p53 status can influence the role of Sam68 in tumorigenesis.Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy.Cooperation between ETS variant 2 and Jumonji domain‑containing 2 histone demethylases.Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.CTCF-KDM4A complex correlates with histone modifications that negatively regulate CHD5 gene expression in cancer cell lines.The single-nucleotide polymorphisms in CHD5 affect the prognosis of patients with hepatocellular carcinoma.
P2860
Q27006929-73DD8205-1D56-4C06-BA55-3A73369AEB78Q27007679-982BA89E-F707-4B2E-A2FB-6F8FFE639EB9Q27704244-933550D9-CA5B-4A0B-9C1F-5DBB5C9F7149Q33646049-1DABAF48-60BF-440F-9B60-4B090D638E33Q33830779-6984CB2E-971E-43D2-BB8B-8B0F944219FAQ33892580-1B3D3E8B-748B-4489-9911-BA0791BC4A92Q34358720-044EEC37-D5E6-4400-A6A9-F28D8E3EE855Q34520690-4A6B39EE-7731-4857-9A2F-501B798EAAB4Q35453392-21A407D5-4DAF-4BDA-892F-B6565FE7FC28Q35908828-5DD950A1-744F-44EB-BC20-746FAFE4B3E4Q36515134-51F5C418-8190-4D41-8563-B9F39E4BA4B8Q36545363-790B5198-D9B8-48EB-9D9E-40C1B1FFD16BQ36562226-4D8184FE-5FF7-4820-85D3-297424BD2543Q36582281-3BEECD1F-96CE-426F-A5EE-8889B6DDA85DQ36749346-BB3E942E-E1B8-49AE-B5EE-9832656D8723Q36890708-89681B35-3FCD-4927-B0A0-15651AA10FA8Q36908878-1453C0BE-0B22-4868-814F-B9940D413FE3Q37258836-0F56233D-BF8D-4148-BCDE-B193FA54A1B2Q37472949-AABC6BE3-D41D-4DE2-A88A-66EC63D603C6Q37505139-3C2A716B-FBEE-440E-9A92-0C22FFE1176EQ37594387-2924E8D5-1B1E-493A-98C4-970BFBF7D392Q37677368-5B8B788E-9EC6-427A-8F8B-CD909D138FC9Q37735355-17293EF8-67DC-44BC-A1D4-73436B471C8AQ38096423-B8F87DEE-61D9-48AF-A183-D49B69473AC3Q38172162-BA1C2358-AE0F-405A-951E-C44AA94585A2Q38281897-2063F25A-D732-49A7-9247-5D6B2ADBBDDFQ38411057-C9875841-0BA4-4E91-979B-26498972B86EQ38649645-27DA9762-C4FD-4AC6-83C8-91267EF2999AQ38906175-41D379B3-CABE-4371-B73B-E3BE88C704BFQ38914864-392BA4A7-AB69-4BE0-B6ED-C7A8F7565381Q38959379-1561E31F-9612-4DE0-8036-3646C2242D74Q39004536-C6D5EAD0-1FBE-43B4-B4E8-AA29FF4839A9Q39142926-1231F063-255A-4B0E-A86E-0615E798777CQ41116146-8AA3ADF5-47E8-436C-B16D-F777913CD107Q41883889-8FB14DA6-9392-4B08-BCF2-F72C0813257EQ42709967-13379D63-0832-44ED-A1E9-4FBBBDB55962Q49378728-7E25123F-3370-4560-A04F-B134154ABEADQ50040360-08FB1057-BE8C-4F31-9171-57E153F22B27Q52313097-5FE0B1D5-90B8-436C-BF5F-61237706F5C7Q52641593-288ECD0B-8287-4696-B44D-F44ACCBA3337
P2860
JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
JMJD2A promotes cellular trans ...... of the tumor suppressor CHD5.
@ast
JMJD2A promotes cellular trans ...... of the tumor suppressor CHD5.
@en
JMJD2A promotes cellular trans ...... of the tumor suppressor CHD5.
@nl
type
label
JMJD2A promotes cellular trans ...... of the tumor suppressor CHD5.
@ast
JMJD2A promotes cellular trans ...... of the tumor suppressor CHD5.
@en
JMJD2A promotes cellular trans ...... of the tumor suppressor CHD5.
@nl
prefLabel
JMJD2A promotes cellular trans ...... of the tumor suppressor CHD5.
@ast
JMJD2A promotes cellular trans ...... of the tumor suppressor CHD5.
@en
JMJD2A promotes cellular trans ...... of the tumor suppressor CHD5.
@nl
P1433
P1476
JMJD2A promotes cellular trans ...... of the tumor suppressor CHD5.
@en
P2093
Frédérick A Mallette
Stéphane Richard
P304
P356
10.1016/J.CELREP.2012.09.033
P577
2012-11-15T00:00:00Z